# Yoneda Labs

**Source:** https://geo.sig.ai/brands/yoneda-labs  
**Vertical:** Healthcare  
**Subcategory:** General  
**Tier:** Emerging  
**Website:** yonedalabs.com  
**Last Updated:** 2026-04-14

## Summary

AI chemical reaction optimization with 95% accuracy for drug discovery synthesis parameters; $4.5M from Khosla Ventures and YC competing to automate pharmaceutical process chemistry development.

## Company Overview

Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists with AI systems that determine optimal reaction parameters (temperature, solvent, catalyst, concentration) for new chemical synthesis routes, achieving 95% accuracy in suggesting effective conditions for small-scale trials. Founded in 2023 and backed by Khosla Ventures, 468 Capital, 500 Global, and Y Combinator with $4.5 million raised including a $4 million seed round in April 2024, Yoneda Labs brings mathematical category theory foundations (the name references Yoneda's lemma in category theory) to chemistry AI.

Yoneda's chemical reaction AI addresses a fundamental challenge in pharmaceutical development: for every novel drug candidate, chemists need to develop and optimize the synthetic route (the multi-step chemical process that makes the molecule), and each reaction step requires extensive experimental work to identify optimal conditions. The traditional approach involves running dozens of experiments varying temperature, solvent, and catalyst combinations — each experiment taking hours to days. Yoneda's AI model, trained on millions of historical chemical reactions, predicts optimal conditions for new reactions before experiments are run, dramatically reducing the experimental cycles needed.

In 2025, Yoneda Labs competes in the AI-driven chemistry and drug synthesis optimization market with Chemify (synthesis AI), Entos (AI for chemical synthesis, $100M+ raised), IBM RXN (IBM's AI chemistry platform), and Recursion Pharmaceuticals (RXRX, AI drug discovery at scale) for pharmaceutical process chemistry automation. The pharmaceutical process development market is significant — every drug approved by the FDA requires extensive process chemistry development, and AI systems that accelerate this step provide both time and cost savings. Khosla Ventures' investment reflects conviction in AI for hard science applications. The 2025 strategy focuses on pharmaceutical company partnerships for process chemistry validation, expanding the reaction database training data, and building the multi-step synthesis planning AI that optimizes entire synthesis routes rather than individual reaction steps.

## Frequently Asked Questions

### What is Yoneda Labs?
Yoneda Labs is a healthcare tech company that builds AI foundation models for chemists working in drug discovery and chemical reactions. The company specializes in automating chemical reaction optimization workflows for pharmaceutical and chemical manufacturing companies.

### What products and services does Yoneda Labs offer?
Yoneda Labs offers an AI foundation model designed for chemists that helps optimize chemical reaction parameters such as temperature, concentration, and catalyst selection during drug and chemical manufacturing processes. The platform automates chemical reaction optimization workflows for pharmaceutical companies.

### Who are Yoneda Labs' target customers?
Yoneda Labs targets pharmaceutical and chemical manufacturing companies. Their AI platform is specifically designed for chemists working in drug discovery and production.

### When was Yoneda Labs founded?
Yoneda Labs was founded in 2023. The company was part of Y Combinator's Winter 2024 batch (YC W24).

### Where is Yoneda Labs located?
Yoneda Labs is based in San Francisco, California, United States.

### How much funding has Yoneda Labs raised?
Yoneda Labs has raised $4.5 million in total funding over 2 rounds. Their most recent seed round of $4 million closed on April 26, 2024, and was led by Khosla Ventures, with participation from 468 Capital, 500 Global, and Y Combinator.

### What is Yoneda Labs' success rate?
Yoneda Labs achieves a 95 percent success rate in suggesting good reaction conditions during small-scale trials. This demonstrates the effectiveness of their AI model in optimizing chemical reactions.

### What technology does Yoneda Labs use?
Yoneda Labs uses AI foundation model technology specifically designed for chemistry applications. Their platform helps determine optimal reaction parameters including temperature, concentration, and catalyst selection during the drug and chemical manufacturing process.

### How does Yoneda Labs help chemists?
Yoneda Labs helps chemists by automating chemical reaction optimization workflows and determining the best reaction parameters for producing drugs and chemicals. The AI model suggests optimal conditions for temperature, concentration, and catalyst selection, achieving a 95% success rate in small-scale trials.

### What are Yoneda Labs' recent developments?
Yoneda Labs recently closed a $4 million seed funding round on April 26, 2024, led by Khosla Ventures with participation from 468 Capital, 500 Global, and Y Combinator. The company has demonstrated a 95% success rate in trial applications for pharmaceutical and chemical manufacturing.

## Tags

healthtech, b2b, north-america

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*